Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of MK-0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Anacetrapib (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia; Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 18 Nov 2009 Results were reported at the 82nd Annual Scientific Sessions of the American Heart Association.
- 18 Nov 2009 Updated results reported at the 82nd Annual Scientific Sessions of the American Heart Association.
- 08 Oct 2007 Drug name changed from MK 0859 to anacetrapib.